Luca Mastorino

University of Turin

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (21)

Collaborators (4)

francois rosset

University of Turin

simone ribero

University of Turin

Paolo Gisondi

University of Verona

Umberto Santaniello

University of Turin

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Luca Mastorino

Research Interests

Explore related searches

Contact this professor

Articles (21)

Collaborators (4)

francois rosset

simone ribero

Paolo Gisondi

Umberto Santaniello

Make your next move.

Luca Mastorino

Research Interests

Explore related searches

Contact this professor

Articles (21)

Hormonal Therapies in Cosmetic Dermatology: Mechanisms, Clinical Applications, and Future Perspectives

Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence

Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years

Effectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort Study

The Epidemiology of Syphilis Worldwide in the Last Decade

Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study

IL‐17 and IL‐23 inhibitors dose spacing in adult psoriatic patients: a real‐world pilot study

Verlängerung der Dosierungsintervalle von IL‐17‐ und IL‐23‐Inhibitoren bei erwachsenen Patienten mit Psoriasis: eine Pilotstudie aus der Praxis

Switching to brodalumab after failure of IL‐17A inhibitors in psoriatic patients: A real‐life multicentre study

Super Responders in Moderate-to-Severe Atopic Dermatitis Under Treatment with Dupilumab: An Explorative Real-World Study

Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis

‘Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients’‐response to Yu et al.

Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real‐life experience on 638 patients with psoriasis

Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients

Exacerbation of acquired perforating dermatosis following SARS‐CoV‐2 vaccination

Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres

Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis

Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience

Herpes Zoster Infection in Atopic Patients Undergoing Upadacitinib: Practical Suggestions on Vaccination and Management

Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?

Real‐world data on primary cutaneous lymphoproliferative disorders following SARS‐CoV‐2 vaccination: A multicentre experience from tertiary referral hospitals

Collaborators (4)

francois rosset

simone ribero

Paolo Gisondi

Umberto Santaniello

Make your next move.